Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | FMC-376 |
Synonyms | |
Therapy Description |
FMC-376 inhibits KRAS G12C, potentially resulting in decreased tumor growth (Cancer Res (2023) 83 (7_Supplement): 1142). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FMC-376 | FMC376|FMC 376 | KRAS G12C inhibitor 33 | FMC-376 inhibits KRAS G12C, potentially resulting in decreased tumor growth (Cancer Res (2023) 83 (7_Supplement): 1142). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06244771 | Phase Ib/II | FMC-376 | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors (PROSPER) | Recruiting | USA | 0 |